Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by princeofcuton Aug 11, 2015 12:52pm
68 Views
Post# 24007336

RE:RE:challenge to the pumpertrasholes...

RE:RE:challenge to the pumpertrasholes...ROTFLMAO..goofynewfie tanks for laugh bye...if you notice i am satisfied with the potential science of 208, my concerns are focussed on the competence of RVX leadership to create wealth for shareholders, period...and in that item (the most key of all) RVX leadership IMO is very dismal and deficient...now let me again go back to ODD to show you...the process is straightforward you apply to the FDA to gain ODD status for some malady that has a very small patient pop (under 200K and other limiting factors i believe) in 90 days (as per FDA,) the FDA gives you a yes or no answer...ODD can be very valuable for a company and i follow one biotech that has a +B valuation and it is now just applying for marketing approval..as best i know RVX has been pumping ODD since at least early this year and mutliple 90 day periods have come and gone and still no ODD now why is that.... IMO RVX was pumping ODD before they even made an application to the FDA or else they applied and were turned down (and failed to tell shareholders)...either way IMO it indicates a lack of competence.and PS my call of price collapse following involvement with HEPA have been what perfect or very close to it...but tanks for da laff bye
Bullboard Posts